Changes of Immunological Parameters with Administration of Japanese Kampo Medicine (Juzen-Taihoto/TJ-48) in Patients with Advanced Pancreatic Cancer

Overview

Journal Int J Clin Oncol

Specialty Oncology

Date 2013 Feb 28

PMID 23443635

Citations 17

Authors

Tetsuya Ikemoto

Mitsuo Shimada

Shuichi Iwahashi

Yu Saito

Mami Kanamoto

Hiroki Mori

Yuji Morine

Satoru Imura

Tohru Utsunomiya

Affiliations

Soon will be listed here.

Abstract

Background: The prognosis of pancreatic cancer is extremely poor regardless of various combination therapies. Immunoaugumentation against tumor cells was recently A focus. We reported that the population of Foxp3(+)CD25(+)CD4(+) regulatory T cells (Foxp3(+)Treg) was the new parameter for the estimation of host immunity and had correlation with tumor aggressiveness. Here we show the immunoaugumentation effects of Japanese Kampo medicine, Juzen-Taihoto/TJ-48, empirically considered as an immunoaugumentation drug, with investigation of Treg and other immunological parameters.

Patients And Method: Peripheral Foxp3(+) Treg populations, CD4/CD8 ratio, and CD57(+) cells (NK cells) populations in advanced pancreatic cancer patients (n = 30, stage VI A and B according to TNM classification) were estimated after TJ-48 administration for 14 days before the anti-cancer therapy.

Results: Treg populations were significantly increased compared to healthy donors (Mann-Whitney U test, P < 0.001). Administration of Juzen-Taihoto/TJ-48 significantly decreased Treg populations (Mann-Whitney U test, P < 0.001) and increased the CD4/CD8 ratio (Mann-Whitney U test, P < 0.01), even though CD57(+) cell populations did not change significantly.

Conclusions: Juzen-Taihoto/TJ-48 increased regulatory activities in T cells through decreasing Foxp3(+) Treg populations in advanced pancreatic cancer patients. This effect can lead to immunoaugumentation for various combination therapies.

Citing Articles

Prolonged survival by combination treatment with a standardized herbal extract from Japanese Kampo-medicine (Juzentaihoto) and gemcitabine in an orthotopic transplantation pancreatic cancer model.

Napp J, Siebel P, Rausch H, Kuchta K, Efferth T, Alves F Front Oncol. 2024; 14:1454291.

PMID: 39723364 PMC: 11669038. DOI: 10.3389/fonc.2024.1454291.

Koshiishi T, Nishioka N, Yoshimoto K Asian Pac J Cancer Prev. 2024; 25(7):2291-2295.

PMID: 39068560 PMC: 11480620. DOI: 10.31557/APJCP.2024.25.7.2291.

Anticancer Mechanism of Polysaccharide and Its Application in Cancer Immunotherapy.

He Z, Liu X, Qin S, Yang Q, Na J, Xue Z Pharmaceuticals (Basel). 2024; 17(5).

PMID: 38794206 PMC: 11124422. DOI: 10.3390/ph17050636.

Current status of Complementary and Alternative Medicine Interventions in the Management of Pancreatic Cancer - An Overview.

Tarasiuk A, Mirocha G, Fichna J Curr Treat Options Oncol. 2023; 24(12):1852-1869.

PMID: 38079061 PMC: 10781793. DOI: 10.1007/s11864-023-01146-4.

Recent Advances in (Licorice)-Containing Herbs Alleviating Radiotherapy- and Chemotherapy-Induced Adverse Reactions in Cancer Treatment.

Wang K, Yu Y, Chen H, Chiang Y, Ali M, Shieh T Metabolites. 2022; 12(6).

PMID: 35736467 PMC: 9227067. DOI: 10.3390/metabo12060535.

References

Fujiki K, Nakamura M, Matsuda T, Isogai M, Ikeda M, Yamamoto Y . IL-12 and IL-18 induction and subsequent NKT activation effects of the Japanese botanical medicine Juzentaihoto. Int J Mol Sci. 2009; 9(7):1142-1155. PMC: 2635730. DOI: 10.3390/ijms9071142. View

Ikemoto T, Sugimoto K, Takita M, Shimoda M, Noguchi H, Naziruddin B . Japanese herbal medicine TJ-48 prevents autoimmune diabetes in NOD mice. Am J Chin Med. 2011; 39(4):743-56. DOI: 10.1142/S0192415X11009160. View

Hori S, Nomura T, Sakaguchi S . Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003; 299(5609):1057-61. DOI: 10.1126/science.1079490. View

Lepisto A, Moser A, Zeh H, Lee K, Bartlett D, McKolanis J . A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther. 2009; 6(B):955-964. PMC: 2614325. View

Hisha H, Kohdera U, Hirayama M, Yamada H, Fan T, Cui Y . Treatment of Shwachman syndrome by Japanese herbal medicine (Juzen-taiho-to): stimulatory effects of its fatty acids on hemopoiesis in patients. Stem Cells. 2002; 20(4):311-9. DOI: 10.1634/stemcells.20-4-311. View

Ikemoto T, Shimada M, Komatsu M, Yamada S, Saito Y, Mori H . Indoleamine 2,3-dioxygenase affects the aggressiveness of intraductal papillary mucinous neoplasms through Foxp3+CD4+CD25+ T cells in peripheral blood. Pancreas. 2012; 42(1):130-4. DOI: 10.1097/MPA.0b013e3182575e4a. View

Morine Y, Shimada M, Ikegami T, Imura S, Kanemura H, Arakawa Y . Usefulness of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients for unresectable biliary carcinoma. Hepatogastroenterology. 2009; 56(90):307-12. View

Takeda T, Yamaguchi T, Yaegashi N . Perceptions and attitudes of Japanese gynecologic cancer patients to Kampo (Japanese herbal) medicines. Int J Clin Oncol. 2011; 17(2):143-9. DOI: 10.1007/s10147-011-0271-x. View

Dai Y, Kato M, Takeda K, Kawamoto Y, Akhand A, Hossain K . T-cell-immunity-based inhibitory effects of orally administered herbal medicine juzen-taiho-to on the growth of primarily developed melanocytic tumors in RET-transgenic mice. J Invest Dermatol. 2001; 117(3):694-701. DOI: 10.1046/j.0022-202x.2001.01457.x. View

10.

Ikegami F, Sumino M, Fujii Y, Akiba T, Satoh T . Pharmacology and toxicology of Bupleurum root-containing Kampo medicines in clinical use. Hum Exp Toxicol. 2006; 25(8):481-94. DOI: 10.1191/0960327106het654oa. View

11.

Moretta A, Biassoni R, Bottino C, Mingari M, Moretta L . Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol Today. 2000; 21(5):228-34. DOI: 10.1016/s0167-5699(00)01596-6. View

12.

Makino T, Hishida A, Goda Y, Mizukami H . Comparison of the major flavonoid content of S. baicalensis, S. lateriflora, and their commercial products. J Nat Med. 2008; 62(3):294-9. DOI: 10.1007/s11418-008-0230-7. View

13.

Tani M, Kawai M, Terasawa H, Ina S, Hirono S, Shimamoto T . Prognostic factors for long-term survival in patients with locally invasive pancreatic cancer. J Hepatobiliary Pancreat Surg. 2007; 14(6):545-50. DOI: 10.1007/s00534-007-1209-6. View

14.

Ferrone C, Brennan M, Gonen M, Coit D, Fong Y, Chung S . Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg. 2007; 12(4):701-6. DOI: 10.1007/s11605-007-0384-8. View

15.

Wood K, Sakaguchi S . Regulatory T cells in transplantation tolerance. Nat Rev Immunol. 2003; 3(3):199-210. DOI: 10.1038/nri1027. View

16.

Ikemoto T, Yamaguchi T, Morine Y, Imura S, Soejima Y, Fujii M . Clinical roles of increased populations of Foxp3+CD4+ T cells in peripheral blood from advanced pancreatic cancer patients. Pancreas. 2006; 33(4):386-90. DOI: 10.1097/01.mpa.0000240275.68279.13. View

17.

OLeary J, Goodarzi M, Drayton D, von Andrian U . T cell- and B cell-independent adaptive immunity mediated by natural killer cells. Nat Immunol. 2006; 7(5):507-16. DOI: 10.1038/ni1332. View

18.

Bignone P, Banham A . FOXP3+ regulatory T cells as biomarkers in human malignancies. Expert Opin Biol Ther. 2008; 8(12):1897-920. DOI: 10.1517/14712590802494022. View

19.

Imamura M, Doi R, Imaizumi T, Funakoshi A, Wakasugi H, Sunamura M . A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer. Surgery. 2004; 136(5):1003-11. DOI: 10.1016/j.surg.2004.04.030. View

20.

Bao P, Ramanathan R, Krasinkas A, Bahary N, Lembersky B, Bartlett D . Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer. Ann Surg Oncol. 2010; 18(4):1122-9. DOI: 10.1245/s10434-010-1401-9. View